- Email: [email protected]
Effects of the 5-HT1B receptor agonist CP 94253 on methamphetamine self-administration
e78
CPDD 77th Annual Meeting Abstracts (2015) / Drug and Alcohol Dependence 156 (2015) e2–e101
1.03–2.04), and non-medical use of prescription drugs (AOR = 1.55, 95% CI: 1.16–2.07). In contrast, CSA was not an independent correlate of use of these illicit drugs among males. Conclusions: CSA appears to influence the risk of adulthood illicit drug use among females but not males. The findings suggest incorporation of trauma-informed approaches may improve drug use prevention interventions for females. Financial support: NIDA R01DA036414. http://dx.doi.org/10.1016/j.drugalcdep.2015.07.1128 Effects of the 5-HT1B receptor agonist CP 94253 on methamphetamine self-administration R. Garcia ∗ , N. Pentkowski, J. Venault, K. Leslie, J.P. Bonadonna, A. Cotter, M.F. Olive, J.L. Neisewander School of Life Sciences, Arizona State University, Tempe, AZ, United States Aims: We previously found that the selective 5-HT1B receptor (5-HT1BR) agonist, CP 94253 (CP), shifts the cocaine selfadministration (SA) dose-response (DR) curve upward and left during training but produces a downward shift after 3 weeks of forced abstinence. This study examined whether CP has similar effects on methamphetamine (meth) SA. Methods: Twenty male Sprague-Dawley rats were trained to self-administer meth (0.1 mg/kg) on a FR5 schedule. After drug intake stabilized, rats commenced within-session DR training with five doses (0.003, 0.01, 0.03, 0.1, and 0.3 mg/kg). Animals were then treated twice pre- and post-abstinence with CP (5.6 mg/kg, s.c.) or saline (1 mL/kg, s.c.) with order of treatment counterbalanced, to assess CP effects on meth SA. In addition, rats were tested on a progressive ratio (PR) schedule with 0.03 mg/kg meth available to evaluate CP effects on meth incentive motivation. PR testing occurred across two sessions for which rats received pretreatment with 5.6 and 10 mg/kg CP on the first and second sessions, respectively. Results: Pre- and post-abstinence, rats exhibited the typical inverted U-shaped meth SA DR curve with the highest number of infusions obtained at the 0.01 mg/kg dose regardless of pretreatment. Prior to abstinence (n = 10), CP reduced total meth reinforcers obtained for the two highest doses. For post-abstinence (n = 12), CP had similar effects, reducing total reinforcers obtained for the last three highest doses. Paired sample t-tests for breakpoints on PR sessions indicated no significant effect of CP. Conclusions: Unlike the abstinence-dependent modulatory role of 5-HT1BRs on cocaine SA, this study found similar effects of CP pre- and post-abstinence suggesting different mechanisms may regulate meth SA. These findings are important for understanding the clinical efficacy of 5-HT1BR agonists as treatments for psychostimulant disorders. Financial support: R01DA01106415, R01DA025606. http://dx.doi.org/10.1016/j.drugalcdep.2015.07.1129
Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and qualitative analysis of participant accounts Albert P. Garcia-Romeu 1,∗ , Tehseen Noorani 4 , Roland R. Griffiths 2 , Matthew W. Johnson 3 1 Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, United States 2 Departments of Psychiatry and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, United States 3 Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States 4 Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States
Aims: We assessed long-term (>12 months) outcomes of psilocybin-facilitated smoking cessation, and qualitatively analyzed participants’ accounts to inform potential psychological mechanisms of treatment efficacy. Methods: Fifteen individuals who completed a pilot study of psilocybin-facilitated smoking cessation were invited for a longterm follow-up. Eleven (73%) returned and were interviewed about their current smoking and treatment experience (mean time since treatment = 30 months, SD = 17, range = 16–57). Exhaled carbon monoxide, and self-report measures of craving, temptation, and smoking abstinence self-efficacy were assessed. Results: At 6 months, 10 of 11 (91%) participants were smoking abstinent. At long-term follow-up, 9 of 11 (82%) were still abstinent. Craving and temptation were not significantly different between 6-month and long-term follow-ups, and remained significantly lower than at baseline. Smoking abstinence self-efficacy showed significant persisting increases from baseline scores, and remained comparable to those at 6 months. Participants reported profound, insightful psilocybin experiences and good rapport with study staff as factors impacting treatment efficacy. Conclusions: Psilocybin, administered under controlled conditions in a treatment context, is associated with ongoing smoking abstinence and persisting reductions in craving and temptation. Results were potentially related to personally meaningful experiences and rapport with study staff. Results showed lasting benefits in this sample consistent with prior research on long-term effects of psilocybin. Financial support: Heffter Research Institute, Beckley Foundation, NIDA T32DA07209 and R01DA003889. http://dx.doi.org/10.1016/j.drugalcdep.2015.07.1130 The role of smoking-specific experiential avoidance in the relation between perceived stress and tobacco use among treatment-seeking smokers Lorra Garey 1,∗ , Michael J. Zvolensky 1 , Norman B. Schmidt 2 1 Department of Psychology, University of Houston, Houston, TX, United States 2 Department of Psychology, Florida State University, Tallahassee, FL, United States
Aims: The present study explored the role of smoking-specific experiential avoidance on the relation between perceived stress and clinically relevant smoking behaviors among treatmentseeking smokers. It was hypothesized that smoking-specific experiential avoidance would have an indirect effect on relations,
CPDD 77th Annual Meeting Abstracts (2015) / Drug and Alcohol Dependence 156 (2015) e2–e101
1.03–2.04), and non-medical use of prescription drugs (AOR = 1.55, 95% CI: 1.16–2.07). In contrast, CSA was not an independent correlate of use of these illicit drugs among males. Conclusions: CSA appears to influence the risk of adulthood illicit drug use among females but not males. The findings suggest incorporation of trauma-informed approaches may improve drug use prevention interventions for females. Financial support: NIDA R01DA036414. http://dx.doi.org/10.1016/j.drugalcdep.2015.07.1128 Effects of the 5-HT1B receptor agonist CP 94253 on methamphetamine self-administration R. Garcia ∗ , N. Pentkowski, J. Venault, K. Leslie, J.P. Bonadonna, A. Cotter, M.F. Olive, J.L. Neisewander School of Life Sciences, Arizona State University, Tempe, AZ, United States Aims: We previously found that the selective 5-HT1B receptor (5-HT1BR) agonist, CP 94253 (CP), shifts the cocaine selfadministration (SA) dose-response (DR) curve upward and left during training but produces a downward shift after 3 weeks of forced abstinence. This study examined whether CP has similar effects on methamphetamine (meth) SA. Methods: Twenty male Sprague-Dawley rats were trained to self-administer meth (0.1 mg/kg) on a FR5 schedule. After drug intake stabilized, rats commenced within-session DR training with five doses (0.003, 0.01, 0.03, 0.1, and 0.3 mg/kg). Animals were then treated twice pre- and post-abstinence with CP (5.6 mg/kg, s.c.) or saline (1 mL/kg, s.c.) with order of treatment counterbalanced, to assess CP effects on meth SA. In addition, rats were tested on a progressive ratio (PR) schedule with 0.03 mg/kg meth available to evaluate CP effects on meth incentive motivation. PR testing occurred across two sessions for which rats received pretreatment with 5.6 and 10 mg/kg CP on the first and second sessions, respectively. Results: Pre- and post-abstinence, rats exhibited the typical inverted U-shaped meth SA DR curve with the highest number of infusions obtained at the 0.01 mg/kg dose regardless of pretreatment. Prior to abstinence (n = 10), CP reduced total meth reinforcers obtained for the two highest doses. For post-abstinence (n = 12), CP had similar effects, reducing total reinforcers obtained for the last three highest doses. Paired sample t-tests for breakpoints on PR sessions indicated no significant effect of CP. Conclusions: Unlike the abstinence-dependent modulatory role of 5-HT1BRs on cocaine SA, this study found similar effects of CP pre- and post-abstinence suggesting different mechanisms may regulate meth SA. These findings are important for understanding the clinical efficacy of 5-HT1BR agonists as treatments for psychostimulant disorders. Financial support: R01DA01106415, R01DA025606. http://dx.doi.org/10.1016/j.drugalcdep.2015.07.1129
Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and qualitative analysis of participant accounts Albert P. Garcia-Romeu 1,∗ , Tehseen Noorani 4 , Roland R. Griffiths 2 , Matthew W. Johnson 3 1 Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, United States 2 Departments of Psychiatry and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, United States 3 Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States 4 Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States
Aims: We assessed long-term (>12 months) outcomes of psilocybin-facilitated smoking cessation, and qualitatively analyzed participants’ accounts to inform potential psychological mechanisms of treatment efficacy. Methods: Fifteen individuals who completed a pilot study of psilocybin-facilitated smoking cessation were invited for a longterm follow-up. Eleven (73%) returned and were interviewed about their current smoking and treatment experience (mean time since treatment = 30 months, SD = 17, range = 16–57). Exhaled carbon monoxide, and self-report measures of craving, temptation, and smoking abstinence self-efficacy were assessed. Results: At 6 months, 10 of 11 (91%) participants were smoking abstinent. At long-term follow-up, 9 of 11 (82%) were still abstinent. Craving and temptation were not significantly different between 6-month and long-term follow-ups, and remained significantly lower than at baseline. Smoking abstinence self-efficacy showed significant persisting increases from baseline scores, and remained comparable to those at 6 months. Participants reported profound, insightful psilocybin experiences and good rapport with study staff as factors impacting treatment efficacy. Conclusions: Psilocybin, administered under controlled conditions in a treatment context, is associated with ongoing smoking abstinence and persisting reductions in craving and temptation. Results were potentially related to personally meaningful experiences and rapport with study staff. Results showed lasting benefits in this sample consistent with prior research on long-term effects of psilocybin. Financial support: Heffter Research Institute, Beckley Foundation, NIDA T32DA07209 and R01DA003889. http://dx.doi.org/10.1016/j.drugalcdep.2015.07.1130 The role of smoking-specific experiential avoidance in the relation between perceived stress and tobacco use among treatment-seeking smokers Lorra Garey 1,∗ , Michael J. Zvolensky 1 , Norman B. Schmidt 2 1 Department of Psychology, University of Houston, Houston, TX, United States 2 Department of Psychology, Florida State University, Tallahassee, FL, United States
Aims: The present study explored the role of smoking-specific experiential avoidance on the relation between perceived stress and clinically relevant smoking behaviors among treatmentseeking smokers. It was hypothesized that smoking-specific experiential avoidance would have an indirect effect on relations,